Search

Displaying results 5051 - 5060 of 10000 in total
  1. Drug

    PN0621

    go.drugbank.com/drugs/DB05218
    Experimental

    PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis. It is being developed by Peptech.

  2. Drug

    PW2101

    go.drugbank.com/drugs/DB06483
    Experimental

    The development of PW2101 has since been discontinued. … The drug was developed by Penwest Pharmaceuticals and in 2005 the FDA issues a Non-Approval letter due to the degree of kinetic variability of PW2101 observed among individuals.

  3. Drug

    Ezatiostat

    go.drugbank.com/drugs/DB05460
    Investigational

    atom of another. … These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen

  4. Drug

    Flurocitabine

    go.drugbank.com/drugs/DB20317
    Experimental

    The usage of the INN stem '-citabine' in the name indicates that Flurocitabine is a nucleoside antiviral or antineoplastic agent, cytarabine or azacitidine derivative. … Flurocitabine has a monoisotopic molecular weight of 243.07 Da.

  5. Drug

    Oxatomide

    go.drugbank.com/drugs/DB12877
    Approved

    Oxatomide has been used in trials studying the treatment of Muscular Dystrophy, Duchenne.

  6. Drug

    Parthenolide

    go.drugbank.com/drugs/DB13063
    ApprovedInvestigational

    Parthenolide has been used in trials studying the diagnostic of Allergic Contact Dermatitis.

  7. Drug

    Volixibat

    go.drugbank.com/drugs/DB13914
    Investigational

    Inhibiting this enzyme results in a decrease of bile acids returning to the liver, which is helpful for the treatment of NASH as abnormal cholesterol metabolism and accumulation of free cholesterol in … Volixibat, also known as SHP626 or LUM002, is an investigational drug that will potentially be used for the treatment of Non-Alcoholic Steatohepatitis (NASH).

  8. Drug

    Emrusolmin

    go.drugbank.com/drugs/DB13927
    Investigational

    Emrusolmin restores hippocampal synaptic and transcriptional plasticity as well as spatial memory in a mouse model for Alzheimer's disease, when given orally before or after the onset of pathology.

  9. Drug

    Streptococcus pneumoniae type 22F capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB16710
    ApprovedInvestigational

    * serotype 22F individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of *Corynebacterium diphtheriae* strain C7 (β197). … Streptococcus pneumoniae type 22F capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae

  10. Drug

    Mersalyl

    go.drugbank.com/drugs/DB09338
    Experimental

    The sodium salt of a mercury-containing derivative of salicylamide, was formerly used (often in combination with theophylline) to treat edema, due to its powerful diuretic properties [L1577]. … Mersalyl is the sodium salt form of mersalyl acid, a mercurial diuretic. It is an outdated drug, and its approval has been discontinued by the FDA.